1YTop 25% of the group
Rank 7 of 63 funds
Return +26.97%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 7No. 1 is SCBGENOME(E) +62.13%
First Plus Healthcare FIF
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
FP HCARE-A invests through the master fund Manulife Global Fund – Healthcare Fund 98.25%
This fundFP HCARE-A
The fund that actually investsManulife Global Fund – Healthcare FundThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Eli Lilly and Co LLY8.91%
Johnson & Johnson JNJ7.53%Fact sheet checked on 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per Manulife fact sheet
Over the past year it was in the top 25% of its group; over 5 years it returned +6.61% per year (Top 25% of the group)
No. 1 is SCBGENOME(E) +62.13%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | 5Y | 7Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +18.76% | +3.78% | +5.44% | +12.19% | +11.67% | +22.41% | +26.97% | +34.35% | +37.71% | +93.03% | +104.87% |
Largest drawdown in the selected period −20.45% Previous peak 24 Jun 2024 (NAV 19.3401) → Trough 7 Aug 2025 (NAV 15.3855) · Back to the previous peak on 25 Jun 2026, after 10 months
Currently −0.22% from the peak NAV of 22.0416 (30 Oct 2026)
Over 5 years, FP HCARE-A returned 0.43 per unit of volatility, ranking 1 of 33 funds · The highest is FP HCARE-A (0.43)
(1) กองทุนเน้นลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศเพียงกองทุนเดียวเฉลี่ยในรอบปีบัญชีไม่น้อยกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิของกองทุน คือ Manulife Global Fund - Healthcare Fund (กองทุนหลัก) บริหารจัดการโดย Manulife Investment Management (US) LLC และเป็นกองทุนที่จดทะเบียนจัดตั้งและซื้อขายในประ… Its largest holdings are หน่วยลงทุนกองทนหลก 98.25% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 25 Mar 2016, its NAV has fallen as much as −20.45% from its peak.
Actual total expense ratio (TER) 2.19% a year, against a ceiling of 3.75%. Management fee 1.87%. Front-end fee 1.50%. (Fact sheet 30 Sep 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase 1,000 THB, subsequent purchases not set. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+5
Hedged at the manager's discretion. As of 30 Sep 2026, 14.65% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · FP HCARE-A: no dividends, TER 2.19% · FP HCARE-D: pays dividends, TER 2.19%
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
ABBVIE ABBV5.39%
AstraZeneca AZN.L4.94%
Medtronic MDT3.94%
Roche ROG3.51%
Thermo Fisher TMO3.16%
McKesson MCK3.10%
GSK2.99%Eli Lilly and Co LLYDiabetes and weight-loss drugs
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
Amgen AMGNHospitals, medicines and medical equipment
ABBVIE ABBVHospitals, medicines and medical equipment
AstraZeneca AZN.LHospitals, medicines and medical equipment
Medtronic MDTHospitals, medicines and medical equipment
Roche ROGHospitals, medicines and medical equipment
Thermo Fisher TMOAn American company selling scientific instruments, reagents and services for laboratories
McKesson MCKGSK GSKHospitals, medicines and medical equipment
Based on the master fund's share of this fund's value (98.25% as of 30 Sep 2026) × each stock's weight in the master fund · fact sheet from Manulife · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +21.97% per year
This fund has the highest return in its group
| +111.33% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Full year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −0.1 | +3.0 | −3.6 | −2.1 | +2.4 | +6.3 | +1.1 | +1.5 | −0.6 | +10.3 | −0.2 | · | +18.8* |
| 2025 | +5.3 | +2.3 | −3.3 | −3.1 | −6.9 | +1.9 | +1.7 | +1.2 | +1.4 | +4.9 | +9.5 | −2.5 | +12.1 |
| 2024 | +5.9 | +3.5 | +2.2 | −1.6 | +0.7 | +2.5 | −0.9 | +0.2 | −8.1 | −0.2 | +1.0 | −6.8 | −2.5 |
| 2023 | −6.8 | +3.0 | +0.3 | +3.2 | −2.3 | +4.9 | −1.3 | +2.4 | −1.5 | −3.6 | +2.4 | +3.2 | +3.4 |
| 2022 | −7.2 | −3.5 | +8.5 | −0.3 | −1.2 | +0.6 | +6.7 | −5.1 | +1.0 | +6.2 | −4.0 | −2.0 | −1.4 |